Humana (HUM) to Release Earnings on Wednesday

Humana (NYSE:HUM) will be issuing its quarterly earnings data before the market opens on Wednesday, April 24th. Analysts expect the company to announce earnings of $6.06 per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Humana (NYSE:HUM) last announced its quarterly earnings results on Thursday, January 25th. The insurance provider reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.76 by ($0.87). Humana had a return on equity of 19.44% and a net margin of 2.34%. The company had revenue of $26.46 billion during the quarter, compared to analysts’ expectations of $25.47 billion. During the same quarter in the previous year, the firm earned $1.62 EPS. The firm’s revenue for the quarter was up 17.9% compared to the same quarter last year. On average, analysts expect Humana to post $16 EPS for the current fiscal year and $23 EPS for the next fiscal year.

Humana Stock Down 0.9 %

HUM opened at $325.30 on Tuesday. The company has a market capitalization of $39.25 billion, a PE ratio of 16.41, a price-to-earnings-growth ratio of 1.92 and a beta of 0.45. The firm has a 50-day simple moving average of $330.09 and a two-hundred day simple moving average of $399.70. The company has a quick ratio of 1.59, a current ratio of 1.59 and a debt-to-equity ratio of 0.63. Humana has a 52 week low of $299.23 and a 52 week high of $541.21.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a $0.885 dividend. The ex-dividend date is Friday, June 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.09%. Humana’s dividend payout ratio is currently 17.86%.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Barclays reduced their price objective on Humana from $356.00 to $310.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 2nd. Wells Fargo & Company reduced their price target on shares of Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a research report on Monday, April 8th. TD Cowen lowered their price objective on shares of Humana from $427.00 to $396.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. Deutsche Bank Aktiengesellschaft cut shares of Humana from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $595.00 to $360.00 in a research note on Thursday, January 25th. Finally, Argus cut shares of Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, March 13th. Eleven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, Humana presently has a consensus rating of “Hold” and an average target price of $454.63.

Insider Buying and Selling at Humana

In other Humana news, Director Jorge S. Mesquita acquired 545 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was bought at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the acquisition, the director now directly owns 2,578 shares in the company, valued at $946,358.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.29% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.